Cargando…

A Consensus Statement on acromegaly therapeutic outcomes

The 11th Acromegaly Consensus Conference in April 2017 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management of acromegaly were last published in 2014; since then, new pharmacological agents have been developed and...

Descripción completa

Detalles Bibliográficos
Autores principales: Melmed, Shlomo, Bronstein, Marcello D., Chanson, Philippe, Klibanski, Anne, Casanueva, Felipe F., Wass, John A. H., Strasburger, Christian J., Luger, Anton, Clemmons, David R., Giustina, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136157/
https://www.ncbi.nlm.nih.gov/pubmed/30050156
http://dx.doi.org/10.1038/s41574-018-0058-5
_version_ 1783518188730843136
author Melmed, Shlomo
Bronstein, Marcello D.
Chanson, Philippe
Klibanski, Anne
Casanueva, Felipe F.
Wass, John A. H.
Strasburger, Christian J.
Luger, Anton
Clemmons, David R.
Giustina, Andrea
author_facet Melmed, Shlomo
Bronstein, Marcello D.
Chanson, Philippe
Klibanski, Anne
Casanueva, Felipe F.
Wass, John A. H.
Strasburger, Christian J.
Luger, Anton
Clemmons, David R.
Giustina, Andrea
author_sort Melmed, Shlomo
collection PubMed
description The 11th Acromegaly Consensus Conference in April 2017 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management of acromegaly were last published in 2014; since then, new pharmacological agents have been developed and new approaches to treatment sequencing have been considered. Thirty-seven experts in the management of patients with acromegaly reviewed the current literature and assessed changes in drug approvals, clinical practice standards and clinical opinion. They considered current treatment outcome goals with a focus on the impact of current and emerging somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists on biochemical, clinical, tumour mass and surgical outcomes. The participants discussed factors that would determine pharmacological choices as well as the proposed place of each agent in the guidelines. We present consensus recommendations highlighting how acromegaly management could be optimized in clinical practice.
format Online
Article
Text
id pubmed-7136157
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71361572020-04-08 A Consensus Statement on acromegaly therapeutic outcomes Melmed, Shlomo Bronstein, Marcello D. Chanson, Philippe Klibanski, Anne Casanueva, Felipe F. Wass, John A. H. Strasburger, Christian J. Luger, Anton Clemmons, David R. Giustina, Andrea Nat Rev Endocrinol Consensus Statement The 11th Acromegaly Consensus Conference in April 2017 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management of acromegaly were last published in 2014; since then, new pharmacological agents have been developed and new approaches to treatment sequencing have been considered. Thirty-seven experts in the management of patients with acromegaly reviewed the current literature and assessed changes in drug approvals, clinical practice standards and clinical opinion. They considered current treatment outcome goals with a focus on the impact of current and emerging somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists on biochemical, clinical, tumour mass and surgical outcomes. The participants discussed factors that would determine pharmacological choices as well as the proposed place of each agent in the guidelines. We present consensus recommendations highlighting how acromegaly management could be optimized in clinical practice. Nature Publishing Group UK 2018-07-26 2018 /pmc/articles/PMC7136157/ /pubmed/30050156 http://dx.doi.org/10.1038/s41574-018-0058-5 Text en © Springer Nature Limited 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Consensus Statement
Melmed, Shlomo
Bronstein, Marcello D.
Chanson, Philippe
Klibanski, Anne
Casanueva, Felipe F.
Wass, John A. H.
Strasburger, Christian J.
Luger, Anton
Clemmons, David R.
Giustina, Andrea
A Consensus Statement on acromegaly therapeutic outcomes
title A Consensus Statement on acromegaly therapeutic outcomes
title_full A Consensus Statement on acromegaly therapeutic outcomes
title_fullStr A Consensus Statement on acromegaly therapeutic outcomes
title_full_unstemmed A Consensus Statement on acromegaly therapeutic outcomes
title_short A Consensus Statement on acromegaly therapeutic outcomes
title_sort consensus statement on acromegaly therapeutic outcomes
topic Consensus Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136157/
https://www.ncbi.nlm.nih.gov/pubmed/30050156
http://dx.doi.org/10.1038/s41574-018-0058-5
work_keys_str_mv AT melmedshlomo aconsensusstatementonacromegalytherapeuticoutcomes
AT bronsteinmarcellod aconsensusstatementonacromegalytherapeuticoutcomes
AT chansonphilippe aconsensusstatementonacromegalytherapeuticoutcomes
AT klibanskianne aconsensusstatementonacromegalytherapeuticoutcomes
AT casanuevafelipef aconsensusstatementonacromegalytherapeuticoutcomes
AT wassjohnah aconsensusstatementonacromegalytherapeuticoutcomes
AT strasburgerchristianj aconsensusstatementonacromegalytherapeuticoutcomes
AT lugeranton aconsensusstatementonacromegalytherapeuticoutcomes
AT clemmonsdavidr aconsensusstatementonacromegalytherapeuticoutcomes
AT giustinaandrea aconsensusstatementonacromegalytherapeuticoutcomes
AT melmedshlomo consensusstatementonacromegalytherapeuticoutcomes
AT bronsteinmarcellod consensusstatementonacromegalytherapeuticoutcomes
AT chansonphilippe consensusstatementonacromegalytherapeuticoutcomes
AT klibanskianne consensusstatementonacromegalytherapeuticoutcomes
AT casanuevafelipef consensusstatementonacromegalytherapeuticoutcomes
AT wassjohnah consensusstatementonacromegalytherapeuticoutcomes
AT strasburgerchristianj consensusstatementonacromegalytherapeuticoutcomes
AT lugeranton consensusstatementonacromegalytherapeuticoutcomes
AT clemmonsdavidr consensusstatementonacromegalytherapeuticoutcomes
AT giustinaandrea consensusstatementonacromegalytherapeuticoutcomes